Coronavirus information for applicants and offer-holders

We understand that prospective students and offer-holders may have concerns about the ongoing coronavirus outbreak. The University is following the advice from Universities UK, Public Health England and the Foreign and Commonwealth Office.

Read our latest coronavirus information

MSc Model-based Drug Development / Course details

Year of entry: 2020

Course unit details:
PBPK and In Vitro In Vivo Extrapolation (IVIVE) (1) Fundamental Concepts

Unit code PHAR69922
Credit rating 15
Unit level FHEQ level 7 – master's degree or fourth year of an integrated master's degree
Teaching period(s) Variable teaching patterns
Offered by Pharmacy
Available as a free choice unit? No

Overview

This unit provides a focussed introduction to the use of mechanistic pharmacokinetic models, which use mathematical descriptions of physiological processes to predict the fate of drug molecules within the human body. Therefore, the unit addresses two key aspects of IVIVE: 1) developing mathematical representation of key chemical and physiological processes that affect drug molecules in the body, and 2) defining the relationships that link these processes. Implementation of this approach will be described in the following areas:

  • Prediction of drug-drug interactions by extrapolating from in vitro laboratory tests before commencing clinical studies
  • Prediction of oral absorption; guiding the design of oral drug formulations

 

Pre/co-requisites

Unit title Unit code Requirement type Description
Basic Pharmacokinetics and Pharmacodynamics PHAR69921 Pre-Requisite Compulsory

Aims

The unit aims to:

  • Provide background information on in vitro assays used to characterise ADME properties of new drug entities.
  • Indicate the mathematical framework (physiologically-based pharmacokinetics) that is capable of integrating in vitro information with knowledge of the human body to predict pharmacokinetic behaviour.
  • Explain the advantages of physiologically-based mechanistic models and give examples to show how such models have advanced the process of drug development.

Syllabus

Topics outline

Introduction to physiologically-based pharmacokinetics (PBPK) and systems pharmacology

Modelling of in vitro experiments

  • metabolic assays
  • permeability
  • mDDI assay data
  • transporter/transporter-metabolic DDI assay

Quantitative prediction and IVIVE of metabolic clearance

  • Physiology of hepatic and extrahepatic metabolism
  • In vitro-in vivo extrapolation (IVIVE) of metabolism
  • PBPK modelling and simulation (M&S)
  • IVIVE in drug development

Predicting absorption

  • Principles of drug absorption
  • The evolution of PBPK absorption models
  • PBPK M&S of oral formulation effects
  • PBPK M&S in drug and formulation development
  • PBPK M&S of food effects
  • dermal absorption; pulmonary absorption

Drug distribution and binding

  • Principles of drug distribution
  • Models for predicting volume of distribution
  • Whole-body PBPK M&S
  • Drug binding and local tissue concentrations

 

Teaching and learning methods

The unit is delivered over a 6-week period.

·      Lectures

·      Workshops, entailing guided sequences of analysis with interactive discussion with tutor

·      Seminars presenting examples of PBPK in drug development

·      Directed reading

·      Formative-assessed calculation-based coursework (pass/fail)

Summative-assessed calculation-based coursework 

Knowledge and understanding

Students should be able to: 

  • Describe the details of in vitro systems used to characterise drug absorption, distribution, metabolism and excretion.
  • Describe the relationships (scaling) between data obtained from in vitro systems and in vivo observations on ADME.

Intellectual skills

Students should be able to: 

  • Critically analyse observations on plasma drug concentration-time profiles and characterise them quantitatively for the purpose of making inferences between different drugs, different patients, different conditions etc.
  • Identify the reasons for differences in the time-courses of drug effect and plasma drug concentration.
  • Make informed predictions of the behaviour of drugs in body with respect to plasma drug concentration-time profile.
  • Apply basic biostatistical concepts and interpret statistical information arising from clinical trials.

Practical skills

Students should be able to: 

  • Perform calculations using fundamental pharmacokinetic equations
  • Use specialised computer software Simcyp and Matlab along with more general data analysis/presentation software to simulate and explore the effects of covariates on drug and metabolite concentrations in the body.

Transferable skills and personal qualities

Students should be able to: 

  •   extracting key points from scientific literature
  • effective written communication

Assessment methods

Assessment task

Length

How and when feedback is provided

Weighting within unit (if relevant)

 

Formative assessments X 4

~2 hours each

Model answers presented in tutorial

N/A (just need to submit)

Coursework – extrapolation from in vitro and preclinical data

 2 pages

written within 2 weeks; online

20%

Coursework – PBPK model & simulation

 2 pages

written within 2 weeks; online

20%

Case study report and oral presentation – drug development/ clinical application

2 pages

written within 2 weeks; verbal at time of presentation

20%

Exam

1 h

 

40%

 

Recommended reading

Lecture notes cite key research articles and reviews, which include…

Wienkers, L.C. and T.G. Heath (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-33.

Houston, J.B. and A. Galetin (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab. 9:940-51.

Rostami-Hodjegan, A. (2012) Physiologically Based Pharmacokinetics Joined With In Vitro-In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology. Clin Pharmacol Ther 92:50-61.

Jamei, M., S. Marciniak, K. Feng, A. Barnett, G. Tucker, and A. Rostami-Hodjegan (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 5:211-23.

Rowland, M., C. Peck, and G. Tucker (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73.

Zhao, P., M. Rowland, and S.M. Huang (2012) Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92:17-20.

Tsamandouras, N., A. Rostami-Hodjegan, and L. Aarons (2013) Combining the "bottom-up" and "top-down" approaches in pharmacokinetic modelling: Fitting PBPK models to observed clinical data. Br J Clin Pharmacol.

 

Study hours

Scheduled activity hours
Assessment written exam 1
Lectures 12
Practical classes & workshops 22
Tutorials 6
Independent study hours
Independent study 109

Teaching staff

Staff member Role
Adam Darwich Unit coordinator

Return to course details